Evidence map›Paper›PMID 31210948›Full record

ArticleUnited European gastroenterology journal2019

Recurrence rate of hepatocellular carcinoma in patients with treated hepatocellular carcinoma and hepatitis C virus-associated cirrhosis after ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin therapy.

Carmen M Preda, Cristian Baicus, Irina Sandra, Alexandru Oproiu, Teodora Manuc, Ileana Constantinescu, Daniel Gavrila, Mircea Diculescu, Radu Dumitru, Catalin Vasilescu and 4 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in United European gastroenterology journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Review
  8. [Expert consensus on antiviral therapy for HBV/HCV-related hepatocellular carcinoma: a 2021 update].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2021
    Article
  9. Review
  10. United European gastroenterology journal · 2020
    Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Carmen M PredaGastroenterology and Hepatology Department, Clinic Fundeni Institute, Bucharest, Romania.
Cristian BaicusInternal Medicine Department, Colentina Hospital, Bucharest, Romania.
Irina SandraGastroenterology and Hepatology Department, Clinic Fundeni Institute, Bucharest, Romania.
Alexandru OproiuGastroenterology and Hepatology Department, Clinic Fundeni Institute, Bucharest, Romania.
Teodora ManucGastroenterology and Hepatology Department, Clinic Fundeni Institute, Bucharest, Romania.
Ileana ConstantinescuGastroenterology and Hepatology Department, Clinic Fundeni Institute, Bucharest, Romania.
Daniel GavrilaSurgery Department, Clinic Fundeni Institute, Bucharest, Romania.
Mircea DiculescuGastroenterology and Hepatology Department, Clinic Fundeni Institute, Bucharest, Romania.
Radu DumitruRadiology Department, Clinic Fundeni Institute, Bucharest, Romania.
Catalin VasilescuSurgery Department, Clinic Fundeni Institute, Bucharest, Romania.
Cristian TieranuGastroenterology and Hepatology Department, Elias Emergency Hospital, Bucharest, Romania.
Doina IstratescuGastroenterology and Hepatology Department, Clinic Fundeni Institute, Bucharest, Romania.
Theodor VoiosuInternal Medicine Department, Colentina Hospital, Bucharest, Romania.ORCID 0000-0003-3250-4900
Mircea ManucGastroenterology and Hepatology Department, Clinic Fundeni Institute, Bucharest, Romania.
Institutul Clinic Fundeni · ROSpitalul Clinic Colentina · ROClinical Emergency Hospital Bucharest · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Recent studies have suggested a higher recurrence rate of hepatocellular carcinoma (HCC) in patients with a history of HCC and hepatitis C virus (HCV)-associated cirrhosis treated with direct-acting antiviral (DAA) agents. Material and methods: We conducted a prospective analysis of 24 patients with HCV-associated cirrhosis and treated HCC who received ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for 12 weeks. Prior therapies for HCC included resection (9/24 patients), radiofrequency ablation (RFA) (7/24) and trans-arterial chemoembolization (TACE) (8/24). All patients were eligible for treatment if they had no HCC recurrence 6 months after their last procedure. A control group was defined. All patients were followed every 6 months, with dynamic computed tomography and/or magnetic resonance imaging. Results: The sustained virological response rate per protocol was 21/24 (87.5%). The study group included 14 (59%) males, median age 64 years (51-77), 50% with associated non-alcoholic steatohepatitis and 24% with Child-Pugh A6 points. HCC recurrence rate/100 patient-years was lower in the DAA-HCC group versus control: 5.5 versus 24.6% patient-years for the resection+RFA group ( Conclusions: DAA therapy significantly reduced the recurrence rate of HCC and improved survival without recurrence in patients with treated HCV-associated HCC.

Indexed as

Neoplasm Recurrence, Local2-NaphthylamineAgedAnilidesAntiviral AgentsCarbamatesCarcinoma, HepatocellularChemoembolization, TherapeuticCyclopropanesHepatectomyHepatitis C, ChronicHumansLactams, MacrocyclicLiver CirrhosisLiver NeoplasmsMacrocyclic Compounds2-NaphthylamineAnilidesAntiviral AgentsCarbamatesCyclopropanesdasabuvirLactams, MacrocyclicMacrocyclic CompoundsombitasvirparitaprevirProlineRibavirinRitonavirSulfonamidesUracilValinedirect antiviral therapyHepatitis Chepatocellular carcinomaliver cirrhosisombitasvir/paritaprevir/r+dasabuvir+ribavirin

Identifiers

PMID31210948
PMCPMC6545706
OpenAlexW2926618713

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.